European Medicines Agency and Swissmedic extend confidentiality arrangement

  • Email
  • Help

News

14/02/2011

European Medicines Agency and Swissmedic extend confidentiality arrangement

The European Medicines Agency and Swissmedic have extended their confidentiality arrangement for a year. The arrangement allows the two agencies to continue to exchange confidential information relating to the medicines used in the context of the 2009 (H1N1) influenza pandemic.

In February 2010, the two agencies agreed to share confidential scientific and technical information relating to the safety, quality, efficacy and post-authorisation follow-up of medicines used in the context of the pandemic, which was declared in June 2009.

Although the pandemic is now over, the H1N1 flu virus is still circulating and causing disease in Europe. Anti-influenza medicines and vaccines against the H1N1 virus are authorised in the European Union and in Switzerland.

The extended agreement is valid until 9 February 2012.

How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings
    

Tell us more

Related information

Contact point:

Monika Benstetter or Sabine Haubenreisser
Tel. +44 (0)20 7418 8427
E-mail: press@ema.europa.eu